Maxime Dely: Helping Patients Live More Freely with Sickle Cell Disease
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Sickle cell disease: an invisible illness with very real consequences
Often invisible from the outside, sickle cell disease remains one of the most common genetic disorders in France, affecting around 30.000 people. Behind this apparent invisibility lies a chronic condition that can deeply impact daily life.
This disease is caused by a genetic abnormality of hemoglobin, leading to the deformation of some red blood cells. Less flexible, these cells struggle to circulate through small blood vessels, causing pain crises, chronic anemia, and sometimes severe organ complications.
Treatment options are diverse: symptomatic care, prevention of complications, transfusions, and today, the development of gene therapies offering real hope for curative treatment.
Among the most effective approaches, red blood exchange by apheresis makes it possible to remove altered red blood cells and replace them with healthy donor red blood cells. This technique reduces blood viscosity, limits iron overload, and helps space out treatment sessions.
Beyond every protocol, there is one simple goal: helping patients live more freely.”

Other posts featuring Maxime Dely on Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health